BioVaxys Technology (XCNQ:BIOV) Research & Development : C$0.00 Mil (TTM As of Oct. 2024)

View and export this data going back to 2018. Start your Free Trial

What is BioVaxys Technology Research & Development?

Research & Development is the aggregate amount of research and development expenses during the year. BioVaxys Technology's Research & Development for the three months ended in Oct. 2024 was C$0.00 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Oct. 2024 was C$0.00 Mil.

BioVaxys Technology Research & Development Historical Data

The historical data trend for BioVaxys Technology's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioVaxys Technology Research & Development Chart

BioVaxys Technology Annual Data

Trend

Oct18

Oct19

Oct20

Oct21

Oct22

Oct23

Oct24

Research & Development

Get a 7-Day Free Trial

0.24

0.73

0.96

0.13

BioVaxys Technology Quarterly Data
	Jan20	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24	Apr24	Jul24	Oct24
Research & Development	Get a 7-Day Free Trial															-0.03	-	-	-	-

BioVaxys Technology Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Oct. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was C$0.00 Mil.

BioVaxys Technology (XCNQ:BIOV) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

BioVaxys Technology Research & Development Related Terms

Thank you for viewing the detailed overview of BioVaxys Technology's Research & Development provided by GuruFocus.com. Please click on the following links to see related term pages.

BioVaxys Technology Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioVaxys Technology Corp (XCNQ:BIOV) » Definitions » Research & Development

Comparable Companies

Traded in Other Exchanges

BVAXF:USA 5LB:Germany

Address

146 Thirtieth Street, Suite 100, Etobicoke, ON, CAN, M8W 3D4

Website

https://www.biovaxys.com

BioVaxys Technology Corp is a clinical-stage biopharmaceutical company dedicated to improving patient lives with novel immunotherapies based on the DPX immune-educating technology platform and its HapTenix 'neoantigen' tumor cell construct platform, for treating cancers, infectious disease, antigen desensitization, and other immunological fields. The company's clinical stage pipeline includes maveropepimut-S which is in Phase II clinical development for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma (DLBCL) and platinum resistant ovarian cancer, and BVX-0918, a personalized immunotherapeutic vaccine using its proprietary HapTenix 'neoantigen' tumor cell construct platform which is soon to enter Phase I in Spain for treating refractive late-stage ovarian cancer.

Executives

James Passin	Director, Senior Officer
Kenneth Kovan	Senior Officer

BioVaxys Technology Headlines

No Headlines